Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02575807 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer
A Phase 1 study, sponsored by Aduro Biotech.
- Terminated
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT02575807: Clinical Trial Phase 1 study, sponsored by Aduro Biotech.
NCT02575807 is a Phase 1 study that was terminated before completion, run by Aduro Biotech. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02575807, a Phase 1 study, was terminated before completion, sponsored by Aduro Biotech.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This 2-part, Phase 1/2 study will test investigational cancer drugs known as CRS-207, epacadostat (IDO), and pembrolizumab (pembro). The purpose of this study is to find out how safe it is to give the investigational drugs to women with platinum-resistant ovarian, fallopian tube, or peritoneal cancer and if it helps patients with these types of cancer live longer or can help shrink or slow the growth of cancer.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Epacadostat
- BIOLOGICAL CRS-207
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2016-03-08 |
| Est. Completion | 2018-05-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02575807
The ClinicalTrials.gov registry entry for NCT02575807 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aduro Biotech, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT02575807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02575807 about?
NCT02575807 is a clinical study titled "Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer". This 2-part, Phase 1/2 study will test investigational cancer drugs known as CRS-207, epacadostat (IDO), and pembrolizumab (pembro). The purpose of this study is to find out how safe it is to give the investigational drugs to women with platinum-resistant ovarian, fallopian tube, or peritoneal cance...
What is the current status of trial NCT02575807?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2016-03-08. Estimated completion is 2018-05-08.
What interventions are being tested in trial NCT02575807?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Epacadostat (DRUG), CRS-207 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02575807?
This trial is sponsored by Aduro Biotech, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.